Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

Gut microbes may shape overlooked molecules linked to immunity and brain function

MaaT Pharma secures €37.5M EIB financing to accelerate microbiome-driven breakthroughs in cancer care

Fiber may boost efficacy of fecal microbiota transplants for ulcerative colitis

How gut bacteria influence chemotherapy success and side effects

Previewing the PPPP congress: Prof. Francavilla on gut microbiota and gluten-related disorders in children

Fueling the future of microbiome science: inside the Global Grants for Gut Health

Latest News